Data completeness
2/8 — Basic
CHLOROMYCETIN (chloramphenicol) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYCETIN (chloramphenicol) is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial protein synthesis by interfering with amino acid transfer to ribosomes. It is indicated for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The drug demonstrates minimal resistance development in staphylococci and penetrates ocular tissues effectively.
Pre-Launch
Pre-launch positioning in a legacy antibiotic space suggests modest team expansion, with focus on regulatory clearance and market re-entry strategy rather than growth acceleration.
Mechanism of Action
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.